Celldex Therapeutics, Inc. (CLDX)
| Previous Close | 52.10 |
| Open | 52.36 |
| Bid | 52.47 x 900 |
| Ask | 52.69 x 1200 |
| Day's Range | 52.32 - 52.76 |
| 52 Week Range | 11.55 - 56.17 |
| Volume | 12,770 |
| Avg. Volume | 933,282 |
| Market Cap | 2.444B |
| Beta (5Y Monthly) | 3.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.67 |
| Earnings Date | Nov. 03, 2021 - Nov. 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.40 |
- Simply Wall St.
Investors in Celldex Therapeutics (NASDAQ:CLDX) have made a enviable return of 729% over the past three years
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...
- Zacks
Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study
Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.
- GlobeNewswire
Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. The Company intends to utilize the subcutaneous formulation of CDX-0159 in its Phase 2 program in chronic urt
